Semaxanib
As of the edition of 20 October 2026, Semaxanib is a small molecule: stopped in 2013; acts on FLT1, FLT4 and KDR and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2013
- Kind
- Small molecule
- Registered trials
- 31, 4 stopped early
- Disease areas
- Cancer; Urinary and reproductive; Digestive system; Skin and connective tissue; Infections; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company-target row on route B because of this drug.
Companies on route B for this drug
In the product1 company-target row is on route B because of Semaxanib.
See the 1 company-target row on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 10 | 8 | 0 | 1 |
| Phase 2 | 18 | 15 | 0 | 3 |
| Phase 3 | 2 | 1 | 0 | 0 |
| All trials | 31 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Pfizer | Lead sponsor of trials | 1998 to now |